PHASE-1 STUDIES OF MALARIOTHERAPY FOR HIV INFECTON
摘要
Objective.To determine whetmalariotherapy (an old therapy for treatment of neurosyphilis) improves someclinical and lboratory parameters of HIV-positive patients without iatrogenic complications. Methods. Total 8 asymptomatic HIV-1 positives subjects whose CD4 cell counts were over 250 × 10^6 cells/L were selected for the phase-1 studies of malariotherapy and were intravenously injected Plasmodia vivax to induce artifiial malaria.Malaria was terminated with chloroquine fater 10 ～ 20 malarial fever eqisodes.Cell-bound CD4 levels were measured by APAAP (a solid-phase enzyme essay) and levels of neopterin (NPT),beta-2-microglobulin (B2M) soluble tumor tumor necrosis factor receptor-2(sTNF-RⅡ),in-terleukin-2(IL-2) and HIV P24 antigen were mesured by ELISA. Patients were followed up to 24～30 months. Results. CD4 levels increasede in 5, NPT decreased in 7 of 8 patients;IL-2 increased in 5 of 6 patients after malariotherapy. The total trends of B2M and sTNF-RⅡ basically remained stable. HIV P24 antigen remained undetectable in 6,remained detectably low level in 1 and experienced increase in 1 of 8 patients after malariotherapy. No any severe complications occurred in all 8 patients. Conclusion. The results indicate that malariotherapy basically in safe for HIV infection and it seems that the therapy improves some immunological parameters of HIV patients.